NAS:EOLS (USA)
Business Description
Evolus Inc
NAICS : 325411
SIC : 2833
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Compare
Compare
Traded in other countries / regions
EVL.Germany
•
0K16.UK
•
EOLS.USA
Description
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company generates product revenue from the sale of Jeuveau in the US.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.13 | |||||
| Equity-to-Asset | 0.22 | |||||
| Debt-to-Equity | 1.59 | |||||
| Debt-to-EBITDA | -1.07 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.08 | |||||
| Beneish M-Score | -1.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 25.3 | |||||
| 3-Year EPS without NRI Growth Rate | 21.2 | |||||
| 3-Year FCF Growth Rate | 13.1 | |||||
| 3-Year Book Growth Rate | -21.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.69 | |||||
| 9-Day RSI | 47.87 | |||||
| 14-Day RSI | 44.92 | |||||
| 6-1 Month Momentum % | 49.26 | |||||
| 12-1 Month Momentum % | 24.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.6 | |||||
| Quick Ratio | 2.36 | |||||
| Cash Ratio | 1.64 | |||||
| Days Inventory | 32.15 | |||||
| Days Sales Outstanding | 42.8 | |||||
| Days Payable | 51.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.8 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.44 | |||||
| Operating Margin % | -49.5 | |||||
| Net Margin % | -59.27 | |||||
| ROE % | -98.21 | |||||
| ROA % | -34.3 | |||||
| ROIC % | -70.68 | |||||
| ROC (Joel Greenblatt) % | -1856.95 | |||||
| ROCE % | -44.24 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.06 | |||||
| PB Ratio | 11.55 | |||||
| EV-to-EBIT | -7.22 | |||||
| EV-to-Forward-EBIT | -8.84 | |||||
| EV-to-EBITDA | -7.67 | |||||
| EV-to-Forward-EBITDA | -9.34 | |||||
| EV-to-Revenue | 4.02 | |||||
| EV-to-Forward-Revenue | 3.85 | |||||
| EV-to-FCF | -5.47 | |||||
| Earnings Yield (Greenblatt) % | -13.91 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:EOLS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 132.405 | ||
| EPS (TTM) ($) | -1.41 | ||
| Beta | 1.11 | ||
| Volatility % | 61.78 | ||
| 14-Day RSI | 44.92 | ||
| 14-Day ATR ($) | 0.717546 | ||
| 20-Day SMA ($) | 10.5125 | ||
| 12-1 Month Momentum % | 24.1 | ||
| 52-Week Range ($) | 5.061 - 14.34 | ||
| Shares Outstanding (Mil) | 56.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evolus Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||